Among 9 analysts covering China Unicom (NYSE:CHU), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. China Unicom had 14 analyst reports since July 31, 2015 according to SRatingsIntel. On Monday, August 24 the stock rating was upgraded by Jefferies to “Buy”. The stock of China Unicom (Hong Kong) Limited (ADR) (NYSE:CHU) earned “Hold” rating by Deutsche Bank on Monday, October 24. Jefferies maintained China Unicom (Hong Kong) Limited (ADR) (NYSE:CHU) on Friday, October 23 with “Buy” rating. The firm earned “Buy” rating on Thursday, February 4 by HSBC. The rating was upgraded by Morgan Stanley to “Overweight” on Wednesday, April 6. The firm earned “Hold” rating on Friday, July 31 by HSBC. The firm has “Buy” rating given on Wednesday, March 9 by CLSA. Goldman Sachs upgraded the shares of CHU in report on Thursday, September 22 to “Buy” rating. The firm earned “Hold” rating on Monday, July 18 by Jefferies. The firm earned “Outperform” rating on Friday, March 24 by Macquarie Research. See China Unicom (Hong Kong) Limited (ADR) (NYSE:CHU) latest ratings:
24/03/2017 Broker: Macquarie Research Rating: Outperform Initiate
30/11/2016 Broker: Nomura Old Rating: Buy New Rating: Neutral Downgrade
The stock of TherapeuticsMD Inc (NYSEMKT:TXMD) is a huge mover today! About 800,512 shares traded. TherapeuticsMD Inc (NYSEMKT:TXMD) has declined 25.19% since September 19, 2016 and is downtrending. It has underperformed by 36.85% the S&P500.The move comes after 8 months positive chart setup for the $1.03B company. It was reported on Apr, 26 by Barchart.com. We have $5.44 PT which if reached, will make NYSEMKT:TXMD worth $61.80 million more.
TherapeuticsMD, Inc. is a women’s healthcare firm engaged in creating and commercializing products for women. The company has market cap of $1.03 billion. The Firm is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. It currently has negative earnings. The Company’s drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Analysts await TherapeuticsMD Inc (NYSEMKT:TXMD) to report earnings on May, 2. They expect $-0.11 EPS, 0.00% or $0.00 from last year’s $-0.11 per share. After $-0.12 actual EPS reported by TherapeuticsMD Inc for the previous quarter, Wall Street now forecasts -8.33% EPS growth.
Investors sentiment increased to 1.54 in Q4 2016. Its up 0.22, from 1.32 in 2016Q3. It is positive, as 15 investors sold TherapeuticsMD Inc shares while 35 reduced holdings. 31 funds opened positions while 46 raised stakes. 162.01 million shares or 5.89% more from 152.99 million shares in 2016Q3 were reported. Commerzbank Aktiengesellschaft Fi accumulated 54,128 shares. Moreover, Td Asset Mngmt Inc has 0.01% invested in TherapeuticsMD Inc (NYSEMKT:TXMD) for 525,700 shares. Moreover, California State Teachers Retirement has 0% invested in TherapeuticsMD Inc (NYSEMKT:TXMD) for 309,524 shares. Prudential Financial Incorporated invested in 14,860 shares. Moreover, Stifel Fincl has 0% invested in TherapeuticsMD Inc (NYSEMKT:TXMD) for 190,477 shares. Ameritas Prtn stated it has 0% in TherapeuticsMD Inc (NYSEMKT:TXMD). Massachusetts-based Fmr Ltd Liability Co has invested 0.02% in TherapeuticsMD Inc (NYSEMKT:TXMD). Blackrock Gru invested in 0% or 122,441 shares. Clearline Capital L P has 46,762 shares for 0.12% of their portfolio. Financial Architects has invested 0% in TherapeuticsMD Inc (NYSEMKT:TXMD). Riggs Asset Managment Com owns 10,000 shares. Royal National Bank & Trust Of Canada has invested 0% of its portfolio in TherapeuticsMD Inc (NYSEMKT:TXMD). Great West Life Assurance Co Can holds 0% in TherapeuticsMD Inc (NYSEMKT:TXMD) or 15,700 shares. Cetera Advsr Limited Co owns 34,750 shares. Blackrock Fund Advsr reported 5.83 million shares.
Among 4 analysts covering TherapeuticsMD (NYSEMKT:TXMD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TherapeuticsMD had 6 analyst reports since September 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Tuesday, December 8. The stock of TherapeuticsMD Inc (NYSEMKT:TXMD) has “Buy” rating given on Tuesday, November 22 by Jefferies. The stock of TherapeuticsMD Inc (NYSEMKT:TXMD) has “Outperform” rating given on Tuesday, November 22 by Oppenheimer. Stifel Nicolaus maintained TherapeuticsMD Inc (NYSEMKT:TXMD) rating on Tuesday, December 8. Stifel Nicolaus has “Buy” rating and $14.0 target. The company was maintained on Monday, September 21 by Jefferies.
About 63,323 shares traded. China Unicom (Hong Kong) Limited (ADR) (NYSE:CHU) has risen 12.27% since September 19, 2016 and is uptrending. It has outperformed by 0.60% the S&P500.
